Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Rite Aid Spends $2B on Push Into Pharmacy Benefit Management

By Drug Discovery Trends Editor | February 11, 2015

In this June 20, 2011, file photo, a woman exits a Rite Aid store, in Philadelphia. Rite Aid, announced Wednesday, Feb. 11, 2015, it is expanding from running drugstores into managing pharmacy benefits with a planned, $2 billion purchase of EnvisionRx. (AP Photo/Matt RourkeDrugstore chain Rite Aid will use a $2 billion purchase of EnvisionRx to stretch its reach into managing pharmacy benefits in a deal that also builds its stake in two hot growth areas, specialty pharmaceuticals and Medicare prescription drug coverage.
 
Shares of the nation’s third-largest drugstore chain surged Wednesday after it announced that it will pay $1.8 billion in cash and $200 million in stock for EnvisionRx, a pharmacy benefit manager, or PBM, owned by the investment firm TPG.
 
PBMs run prescription drug plans for customers like employers and insurers. They process mail-order prescriptions and handle bills for prescriptions filled at retail pharmacies. EnvisionRx also offers services in a growing area for prescription drug spending, specialty pharmacy, and a national Medicare prescription drug plan.
 
Rite Aid, which does not have a PBM business, will enter a market brimming with competition from large, national players like Express Scripts Holding Co., which serves about 85 million people, and rival drugstore operator CVS Health Corp.
 
But Chairman and CEO John Standley told analysts Wednesday morning that the deal was a “logical step” for a company that has gained strength over the past few years.
 
The Camp Hill, Pennsylvania-based company runs 4,569 drugstores, a total that trails Walgreen Co. and CVS Health. It has worked aggressively to clean up its performance by paring debt, closing underperforming stores and installing in others a new wellness theme that features more organic food and personal care products, among other items.
 
Wednesday’s announcement came nearly two months after Rite Aid said its fiscal third-quarter earnings jumped 47 percent in a performance that trumped Wall Street expectations.
 
Standley said that by pairing an established retail pharmacy network with a PBM, Rite Aid can provide more benefits that help customers manage their health better.
 
“The dynamics in the marketplace today are reshaping how we must serve our customers,” he said, adding that those customers now control health care decisions and are increasing their focus on cost.
 
The deal also gives Rite Aid stronger footing in the market for specialty drugs, complex and expensive medicines that are becoming a growing source of revenue for drugstore chains.
 
EnvisionRx, which is based in Twinsburg, Ohio, provides benefits for about 21 million people and serves a range of employers, including the supermarket chain Safeway. It is projected to bring in about $5 billion in revenue this year.
 
The boards of directors for both companies have approved the acquisition, which is expected to close in September.
 
Shares of Rite Aid climbed more than 9 percent, or 72 cents, to $8.30 Wednesday morning, while broader trading indexes fell slightly.
 
That stock price, which slipped below $1 in late 2012, soared 49 percent last year, more than quadrupling the 11.4 percent advance of the Standard & Poor’s 500 index.

Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE